HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in bioartificial nerve grafts lacking Wallerian degeneration.

Abstract
Minocycline, a broad-spectrum antimicrobial tetracycline, acts neuroprotectively in ischemia. Recently, however, minocycline has been revealed to have ambiguous effects on nerve regeneration. Thus its effects in a rat sciatic nerve transplantation model and on cultivated Schwann cells stressed by oxygen glucose deprivation (OGD) were studied. The negative effect of minocycline on Wallerian degeneration, the essential initial phase of degeneration/regeneration after nerve injury, that was recently demonstrated, was excluded by using predegenerated nerve and Schwann cell-enriched muscle grafts, both free of Wallerian degeneration. They were compared with common nerve grafts. The principle findings were that in vitro minocycline provided protective effects against OGD-induced death of Schwann cells by preventing permeability of the mitochondrial membrane. It suppressed the OGD-mediated induction of HIF-1alpha and BAX, and stabilized/induced BCL-2. Cytochrome c release and cleavage of procaspase-3 were diminished; release and translocation of AIF and cytotoxic cleavage of actin into fractin were stopped. In common nerve grafts, minocycline, besides its direct anti-ischemic effect, hampered revascularization by down-regulation of MMP9 and VEGF prolonging ischemia and impeding macrophage recruitment. In bioartificial nerve grafts that were free of Wallerian degeneration and revealed lower immunogenicity, minocycline aided the regeneration process. Here, the direct anti-ischemic effect of minocycline on Schwann cells, which are mandatory for successful peripheral nerve regeneration, dominated the systemic anti-angiogenic/pro-ischemic effects. In common nerve grafts, however, where Wallerian degeneration is a prerequisite, the anti-angiogenic and macrophage-depressing effect is an obstacle for regeneration.
AuthorsGerburg Keilhoff, Lorenz Schild, Hisham Fansa
JournalExperimental neurology (Exp Neurol) Vol. 212 Issue 1 Pg. 189-200 (Jul 2008) ISSN: 1090-2430 [Electronic] United States
PMID18501894 (Publication Type: Journal Article)
Chemical References
  • Apoptosis Regulatory Proteins
  • Neuroprotective Agents
  • Vascular Endothelial Growth Factor A
  • Matrix Metalloproteinase 9
  • Minocycline
Topics
  • Animals
  • Apoptosis (drug effects, physiology)
  • Apoptosis Regulatory Proteins (drug effects, metabolism)
  • Bioartificial Organs
  • Cells, Cultured
  • Growth Cones (drug effects, metabolism)
  • Ischemia (drug therapy, physiopathology, prevention & control)
  • Male
  • Matrix Metalloproteinase 9 (drug effects, metabolism)
  • Membrane Potential, Mitochondrial (drug effects, physiology)
  • Minocycline (pharmacology)
  • Muscle, Skeletal (drug effects, metabolism, transplantation)
  • Neovascularization, Physiologic (drug effects)
  • Nerve Regeneration (drug effects, physiology)
  • Neuroprotective Agents (pharmacology)
  • Peripheral Nerves (drug effects, metabolism, transplantation)
  • Rats
  • Rats, Wistar
  • Schwann Cells (drug effects, metabolism)
  • Sciatic Neuropathy (drug therapy, metabolism, physiopathology)
  • Vascular Endothelial Growth Factor A (drug effects, metabolism)
  • Wallerian Degeneration (drug therapy, physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: